Hanson Kristopher sold $608K of MPLT

Hanson Kristopher (General Counsel) sold 16,508 shares of MapLight Therapeutics, Inc. (MPLT) at an average of $36.82 ($36.00–$37.96, $0.61M total) across 7 trades over 2026-07-15 to 2026-07-17.

Original reporting
SEC EDGAR · Hanson Kristopher
Published Jul 17, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 5:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MPLT
Neutral
medium confidence
Mentioned
$MPLT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MPLTNeutralLow
01

Why it matters

The disclosure updates the insider ownership record and may influence sentiment, but it does not change MPLT’s fundamentals or guidance in the text provided.

02

Market read

Traders get a fresh datapoint on insider activity, but there is no accompanying corporate event or new performance information.

03

What to watch

Insider sales can be driven by diversification, tax planning, or pre-scheduled personal liquidity needs; the filing alone does not establish intent or future selling.

Relevance 5/10Novelty 4/10Timing: filed 2026-07-17, covering sales executed 2026-07-15 to 2026-07-17

Background

This is an SEC Form 4 insider transaction for MapLight Therapeutics, Inc., reported by the General Counsel.

Company-level read

Ticker impact

$MPLTNeutralMedium confidence
Context

MapLight Therapeutics insider Hanson Kristopher sold about $607.9K of MPLT shares in multiple open-market trades from 2026-07-15 to 2026-07-17.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on selling or new company fundamentals emerge.

Evidence & confidence

Form 4 discloses transaction size and timing, but it does not provide new operational, regulatory, or financial information; insider sales often have non-informational motives.

Market effects

Minimal, as this is company-specific insider selling without sector-wide signal.

None indicated.

None indicated.

Counterpoint

Absence of a stated 10b5-1 plan could be interpreted by some traders as more discretionary selling, potentially increasing short-term bearish read-through.

Key entities

  • MapLight Therapeutics, Inc.

    Company whose insider sale is disclosed via Form 4.

  • Hanson Kristopher

    General Counsel who sold 16,508 shares of MPLT for about $607,870.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MPLTMed

MapLight Therapeutics 3Q 2026: EPS ($0.97) — 10-Q Summary

MapLight Therapeutics reported a wider net loss of $51.62M in 3Q 2026, up 75.5% YoY, due to increased R&D and clinical trial expenses. Diluted EPS was ($0.97). The company plans a Phase 3 schizophrenia trial and expects Alzheimer’s disease psychosis trial results in 2H 2027. Cash reserves of $463.4M are expected to last through 2028.

$MPLTHigh

MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in the second half 2027 Enrollment ongoing in